Cargando…

Targeting Solid Tumors With BTK Inhibitors

The repurposing of FDA-approved Bruton’s tyrosine kinase (BTK) inhibitors as therapeutic agents for solid tumors may offer renewed hope for chemotherapy-resistant cancer patients. Here we review the emerging evidence regarding the clinical potential of BTK inhibitors in solid tumor therapy. The use...

Descripción completa

Detalles Bibliográficos
Autores principales: Uckun, Fatih M., Venkatachalam, Taracad
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8079762/
https://www.ncbi.nlm.nih.gov/pubmed/33937249
http://dx.doi.org/10.3389/fcell.2021.650414